Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Hits New 52-Week High – Time to Buy?

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $11.16 and last traded at $11.0875, with a volume of 111308 shares changing hands. The stock had previously closed at $11.09.

Wall Street Analyst Weigh In

BAYRY has been the topic of a number of recent research reports. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Zacks Research downgraded shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Finally, Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

The firm has a 50-day simple moving average of $9.33 and a 200-day simple moving average of $8.48. The firm has a market capitalization of $43.86 billion, a PE ratio of -124.10, a PEG ratio of 5.52 and a beta of 0.66. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.13 and a quick ratio of 0.73.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.